Our genetic testing confirmed that the new tumor in 2017 had similar genetic mutations in KRAS, TP53, and CDKN2A compared with the 2011 cancer, but the mutation in ACVR1B was not present in the 2017 sample, and mutant KRAS (copy number 38) and MYC (copy number 76) amplifications were only present in the 2017 sample. This evidence concerns the gene TP53 and neoplasm.